A Research Study to Look Into the Long-term Effect on Weight Loss of CagriSema in People With Obesity
← catalyst calendarNCT06780449 · readout in 740 d
Sponsored by Novo Nordisk A/S (industry) · NVO — their whole pipeline →.
Phase
Phase 3
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
400estimated
Sites
36
Countries
Belgium, Canada, Denmark +3
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-02-10 | actual | When the study began enrolling |
| Primary completion | 2028-08-28 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2028-10-31 | estimated | The whole study's end, after follow-up |
| First posted | 2025-01-17 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-01-20 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Obesity
Interventions
- Drug: Cagrilintide
- Drug: Semaglutide
- Drug: Placebo cagrilintide
- Drug: Placebo semaglutide
Primary outcome
what the primary-completion date above is the date OFRelative change in body weight
measured From baseline (week 0) to week 104
Permalink · NVO's whole pipeline · Catalyst calendar · Every registered study · What changed